December 2, 2025
Top News for Informatics
AMIA Comments on FDA Real-World Performance Monitoring and Equity Assessment of AI-Enabled Medical Devices
AMIA commented on FDA's request for public comment regarding real-world performance evaluation of AI-enabled medical devices. We support lifecycle governance with continuous post-market monitoring to address performance drift across diverse populations and settings. AMIA recommends comprehensive metrics beyond accuracy including clinical outcomes, safety, usability, and equity assessment. We emphasize transparent documentation, bias mitigation to prevent health disparities, and cross-institutional data sharing for aggregate reporting. AMIA's comments mainly referenced our Public Policy Principles and CHAI's Responsible AI Guide for trustworthy healthcare AI.
Member-Only Content
This content is only accessible by current Members. Please log in to view the full content.
Not a Member yet? Learn more about the exclusive benefits you'll receive and join today.